BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Hearing Loss Technology Market: A Rise in Prevalence of Hearing Loss is Expected to Drive the Market

  Incidence of hearing loss is a massive burden on healthcare and governments.

  February 18, 2022

   · 

  4 min read
• Erythropoiesis-stimulating Agents Market: Increasing Incidence of Anemia Cases Worldwide is Driving the Growth of the Market

  The process of formation of red blood cells is termed as erythropoiesis. Erythropoiesis takes place in the bone marrow.

  February 18, 2022

   · 

  5 min read
• Duodenal Stents Market: The metal duodenal stent segment holds a major share of the market

  Duodenal stent is a medical device used to palliate duodenal obstruction. The duodenal stent keeps the sides of the duodenum open and is made of metal, which is expandable like a mesh tube.

  February 18, 2022

   · 

  5 min read
• Sales of Ultrasound-Assisted Liposuction (UAL) To Grow At A 12% CAGR In The Liposuction Surgery Devices Market

  Fact.MR – A Market research and competitive intelligence provider: The global Liposuction surgery devices market is anticipated to register a positive market size CAGR of 11% in the forecast period 2022-2032 and reach a market valuation of US$ 3.78 Bn.

  February 18, 2022

   · 

  6 min read
• The Global Contraceptives Market To Garner A Value Of US$ 37,242.7 Mn By 2025-End

  Fact.MR – A Market research and competitive intelligence provider: The global contraceptives market shall surpass a market valuation of US$ 37,242.7 Mn by the end of 2025.

  February 18, 2022

   · 

  5 min read
• Drug Development

  Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU

  Clinical phase I data on Orion Corporation’s ODM-208, a first-in-class oral, non-steroidal and selective inhibitor of CYP11A1, the first and rate-limiting enzyme of steroid biosynthesis, were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium.

  February 18, 2022

   · 

  3 min read
• Drug Development

  Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program

  Regeneron Pharmaceuticals, Inc. and Sanofi announced a Phase 3 trial evaluating Dupixent® in patients with chronic spontaneous urticaria will stop due to futility, based on a pre-specified interim analysis.

  February 18, 2022

   · 

  21 min read
• Business

  iZafe Group Q4 Interim Report, October-December 2021

  Net sales for the quarter amounted to SEK 220 (84) thousand. The quarter’s sales consist of revenues attributable to the sale of the digital medication robot Dosell.

  February 18, 2022

   · 

  6 min read
• Business

  Azurity Pharmaceuticals Announces Richard Blackburn as New CEO

  Azurity Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing innovative medicines that meet the specific needs of underserved patient segments, announced Richard Blackburn has been appointed Chief Executive Officer, effective February 14, 2022.

  February 18, 2022

   · 

  2 min read
• Drug Development

  Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn’s and Colitis Organization

  Immunic, Inc. today announced that Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium (IMU-838).

  February 18, 2022

   · 

  9 min read